Literature DB >> 3135226

Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis.

A L Williams1, J H Hoofnagle.   

Abstract

The ratio of the serum aspartate to alanine amino-transferase levels (AST/ALT) is often used as a clue to the etiology of the underlying liver disease. This ratio is usually greater than 2.0 in alcoholic liver disease and less than 1.0 in patients with chronic hepatitis and chronic cholestatic syndromes. We analyzed the AST/ALT ratio in 177 patients with various forms of nonalcoholic chronic liver disease who underwent medical evaluation and percutaneous liver biopsy. In the majority of cases of chronic viral hepatitis, the AST/ALT ratio was less than 1.0. However, there was a statistically significant correlation between the AST/ALT ratio and the presence of cirrhosis. Among 100 patients with chronic type B hepatitis, the mean AST/ALT ratio was 0.59 in those without cirrhosis and 1.02 in those with cirrhosis. Furthermore, the AST/ALT ratio often rose to greater than 1.0 when cirrhosis first became manifest. Thus, the finding of an AST/ALT ratio of greater than 1.0 in a patient with nonalcoholic liver disease should suggest the presence of cirrhosis. In addition, the use of the AST/ALT ratio as a means of separating alcoholic and nonalcoholic liver disease must be tempered with the knowledge that this ratio may be less helpful in the presence of cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135226     DOI: 10.1016/s0016-5085(88)80022-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  119 in total

1.  Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases.

Authors:  Woon Geon Shin; Sang Hoon Park; Sun-Young Jun; Jae One Jung; Joon Ho Moon; Jong Pyo Kim; Kyoung Oh Kim; Cheol Hee Park; Tai Ho Hahn; Kyo-Sang Yoo; Jong Hyeok Kim; Choong Kee Park
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

Review 2.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.

Authors:  J Cui; B Ang; W Haufe; C Hernandez; E C Verna; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-04-15       Impact factor: 8.171

4.  The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.

Authors:  Amandeep Singh; Phuc Le; Rocio Lopez; Naim Alkhouri
Journal:  Hepatol Int       Date:  2018-01-09       Impact factor: 6.047

Review 5.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

6.  Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people.

Authors:  Antonio De Vincentis; Luisa Costanzo; Umberto Vespasiani-Gentilucci; Antonio Picardi; Stefania Bandinelli; Luigi Ferrucci; Raffaele Antonelli Incalzi; Claudio Pedone
Journal:  Dig Liver Dis       Date:  2019-02-03       Impact factor: 4.088

7.  Metabolic investigations in patients with hepatitis B and C.

Authors:  Abdul Aziz Mastoi; Bikha Ram Devrajani; Syed Zulfiquar Ali Shah; Qasim Rohopoto; Sikander Ali Memon; Marya Baloch; Ghulam Ali Qureshi; Waqas Sami
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

8.  Influence of gender on the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) in patients with and without hyperbilirubinemia.

Authors:  Jorge R Mera; Beverly Dickson; Mark Feldman
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

Review 9.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

10.  Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease.

Authors:  Han Hyo Lee; Yeon Seok Seo; Soon Ho Um; Nam Hee Won; Hanna Yoo; Eun Suk Jung; Yong Dae Kwon; Sanghoon Park; Bora Keum; Yong Sik Kim; Hyung Joon Yim; Yoon Tae Jeen; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.